GILD
Gilead Sciences, Inc. NASDAQ$131.65
Mkt Cap $165.2B
52w Low $95.30
58.6% of range
52w High $157.29
50d MA $141.16
200d MA $126.58
P/E (TTM)
19.2x
EV/EBITDA
15.7x
P/B
7.2x
Debt/Equity
1.1x
ROE
37.5%
P/FCF
16.1x
RSI (14)
—
ATR (14)
—
Beta
0.40
50d MA
$141.16
200d MA
$126.58
Avg Volume
6.6M
About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | AMC | 1.81 | 1.86 | +2.8% | 147.23 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% | -1.4% | — |
| Oct 30, 2025 | AMC | 2.13 | 2.47 | +16.0% | 118.44 | -2.0% | +1.1% | +3.0% | +3.9% | +3.5% | +4.2% | +5.0% | — |
| Aug 7, 2025 | AMC | 1.96 | 2.01 | +2.6% | 110.28 | +4.5% | +8.3% | +9.2% | +8.8% | +8.9% | +7.9% | +5.1% | — |
| Apr 24, 2025 | AMC | 1.78 | 1.81 | +1.7% | 106.15 | -3.3% | -2.8% | +0.2% | -1.8% | +0.4% | -2.7% | +2.8% | — |
| Feb 11, 2025 | AMC | 1.74 | 1.90 | +9.2% | 96.14 | +5.8% | +7.5% | +10.2% | +8.3% | +9.5% | +12.0% | +17.9% | — |
| Nov 6, 2024 | AMC | 1.53 | 2.02 | +32.0% | 91.69 | +2.5% | +6.8% | +5.3% | +5.8% | +2.9% | +1.0% | +0.5% | — |
| Aug 8, 2024 | AMC | 1.61 | 2.01 | +24.8% | 75.59 | -0.9% | -2.6% | -3.4% | -2.1% | -1.9% | -1.7% | +4.7% | — |
| Apr 25, 2024 | AMC | -1.49 | -1.32 | +11.4% | 65.27 | +0.4% | +0.2% | +1.0% | -0.1% | +0.4% | +0.1% | -2.0% | — |
| Feb 6, 2024 | AMC | 1.76 | 1.72 | -2.3% | 77.72 | -1.9% | -4.2% | -5.0% | -5.2% | -4.2% | -5.4% | -5.2% | — |
| Nov 7, 2023 | AMC | 1.91 | 2.29 | +19.9% | 80.61 | -3.9% | -3.4% | -7.0% | -5.8% | -7.0% | -7.3% | -3.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | Citigroup | Maintains | Buy → Buy | — | $138.99 | $137.99 | -0.7% | +0.0% | +1.1% | +0.6% | -0.3% | -1.0% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $142.09 | $142.38 | +0.2% | -2.2% | -2.2% | -1.2% | -1.6% | -2.5% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $151.40 | $148.93 | -1.6% | -1.0% | -2.5% | -2.8% | -5.0% | -1.6% |
| Feb 11 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | Needham | Maintains | Buy → Buy | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | Truist | Maintains | Buy → Buy | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Jan 27 | Citigroup | Maintains | Buy → Buy | — | $137.78 | $137.54 | -0.2% | +2.3% | +1.4% | +1.3% | +3.0% | +3.7% |
Recent Filings
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics (KYMR) reported Q1 2026 results while advancing its oral degrader candidates KT-621 and KT-579 through clinical development, targeting multiple pipeline milestones this year.
Apr 30
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences is acquiring Arcellx at $115 per share through a tender offer, providing ACLX shareholders a defined exit while consolidating GILD's cell therapy portfolio.
Apr 28
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Tenax Therapeutics' CFO previously led Triangle Pharmaceuticals through its acquisition by Gilead Sciences, demonstrating experience navigating pharma M&A transactions that could benefit Tenax shareholders.
Apr 22
8-K · 8.01
!! High
Arcus Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Gilead's acquisition of Arcus Biosciences faces setback as the STAR-121 trial of domvanalimab and zimberelimab failed to meet futility analysis criteria for first-line lung cancer treatment.
Apr 20
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences' tender offer to acquire Arcellx at $115 per share represents a significant premium and provides shareholders with a clear exit opportunity at a fixed price through April 2026.
Apr 17
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
LYEL's new executive Lang receives competitive compensation ($560K base plus 40% bonus potential) with full 2026 bonus eligibility, signaling board confidence in his leadership and commitment to retention during critical strategic execution.
Apr 15
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences is acquiring Arcellx at $115 per share in cash, valuing the cell therapy company at approximately $2.1 billion.
Apr 1
8-K
Unknown — 8-K Filing
Assembly Biosciences' optimistic 2025 guidance and pivot toward viral disease therapeutics could drive share appreciation if pipeline candidates advance, but investors should verify clinical progress claims against actual trial data.
Mar 19
8-K
Lyell Immunopharma, Inc. -- 8-K Filing
Lyell Immunopharma appointed a new executive officer with participation in the company's severance plan, potentially affecting shareholder equity structure and executive compensation costs.
Mar 9
SC TO-T
!!! Very High
Arcellx, Inc. -- Tender Offer
Gilead Sciences is acquiring Arcellx for $115 per share in cash, representing a significant premium that validates Arcellx's cell therapy platform and expands Gilead's oncology portfolio.
Mar 6
Data updated apr 25, 2026 11:27am
· Source: massive.com